Airway obstruction

National Choking Awareness Day

Retrieved on: 
Monday, March 18, 2024
Choking, Emergency, Life, Safety, Knowledge, Airway obstruction, Caregiver, Birth control

NESCONSET, N.Y., March 18, 2024 /PRNewswire/ -- As National Choking Awareness Day approaches on March 28th, LifeVac proudly stands at the forefront of life-saving innovation, championing its mission to prevent choking-related tragedies worldwide.

Key Points: 
  • NESCONSET, N.Y., March 18, 2024 /PRNewswire/ -- As National Choking Awareness Day approaches on March 28th, LifeVac proudly stands at the forefront of life-saving innovation, championing its mission to prevent choking-related tragedies worldwide.
  • "We are deeply honored to play a pivotal role in preserving lives on National Choking Awareness Day and every day," remarked Arthur Lih, Inventor and CEO at LifeVac.
  • LifeVac's impact extends beyond its revolutionary device, encompassing comprehensive education and awareness initiatives to equip individuals with the knowledge and tools needed to respond effectively to choking emergencies.
  • As National Choking Awareness Day approaches, LifeVac reaffirms its unwavering commitment to championing safety, innovation, and life preservation.

Lung Stent Market to reach $333.8 million, globally, by 2030 at 7.1% CAGR: Coherent Market Insights

Retrieved on: 
Tuesday, February 20, 2024
Boston Scientific, Cook Group, Research, Neoplasm, Traction, Inflammation, Hospital, Quality of life, Stainless steel, Growth, Airway obstruction, Pneumonia, Risk, Chronic obstructive pulmonary disease, Prevalence, Metal, Stent, Patient, Lung cancer, Medtronic, COPD, Uranium mining

The tracheobronchial stents segment is expected to hold a dominant position in the lung stent market.

Key Points: 
  • The tracheobronchial stents segment is expected to hold a dominant position in the lung stent market.
  • Metal lung stents are expected to dominate the lung stent market in terms of material type.
  • The increasing prevalence of lung diseases, such as lung cancer and pneumonia, is driving the demand for metal lung stents.
  • Tracheobronchial stents and metal lung stents are projected to be the key market opportunities, while North America is expected to dominate the market.

Saving Lives Through Communication, Heroic Faith Medical Science Showcasing Novel AI Auscultation Tool for Procedural Sedation Patients in PGA 77

Retrieved on: 
Tuesday, December 5, 2023
Capnography, Research, Safety, Anesthesia, Pediatrics, Nursing, Incidence, Chief Dental Officer (Canada), Privacy, Surgeon, Respiratory rate, NORA, Cleveland Clinic, Patient, Stethoscope, Multimedia, Airway obstruction, Algorithm, FDA, Esophagogastroduodenoscopy, Faith, Communication, Software, Speech, Patent, ASA, AI, Intubation, Colonoscopy, Apnea, Friction, Medical device, Dentistry, Anesthesiology

The company's proprietary Airmod system, an active noise-canceling electronic stethoscope that seamlessly integrates with AI, enables continuous monitoring of patients' breathing sounds.

Key Points: 
  • The company's proprietary Airmod system, an active noise-canceling electronic stethoscope that seamlessly integrates with AI, enables continuous monitoring of patients' breathing sounds.
  • In collaboration with Taiwan's major medical centers and teaching hospitals, Heroic Faith has collected over 1.6 million entries of breathing sound data for AI training.
  • Heroic Faith's new General Manager, Yuan-Ren Cheng, has recently updated the company's motto from 'Saving Lives Through Innovation' to 'Saving Lives Through Communication.'
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/saving-lives-through-communicat...
    SOURCE Heroic Faith Medical Science, Inc.

Aerin Medical Supports AAO-HNS Position Recognizing Nasal Valve Repair as a Distinct Procedure that Improves Nasal Obstruction Symptoms

Retrieved on: 
Tuesday, April 18, 2023
Research, Medical Devices, Surgery, Medical Supplies, FDA, Other Health, General Health, Health, Science, Other Science, ENT, American Academy of Otolaryngology–Head and Neck Surgery, Failure, AAO, NVC, Otorhinolaryngology, Airway obstruction, American Academy, Multimedia, Nose, Network congestion, Patient, Physician, Steroid, NAO, Ear, Pharmaceutical industry

The statement recognizes nasal valve repair as “a distinct surgical procedure that can improve nasal obstruction symptoms for appropriately selected patients.” The Academy notes that office-based techniques, including radiofrequency treatment, can stabilize the nasal valve, optimize nasal valve collapse (NVC) patient outcomes, and be performed either as a standalone procedure or in combination with other procedures to potentially avoid multiple surgeries.

Key Points: 
  • The statement recognizes nasal valve repair as “a distinct surgical procedure that can improve nasal obstruction symptoms for appropriately selected patients.” The Academy notes that office-based techniques, including radiofrequency treatment, can stabilize the nasal valve, optimize nasal valve collapse (NVC) patient outcomes, and be performed either as a standalone procedure or in combination with other procedures to potentially avoid multiple surgeries.
  • View the full release here: https://www.businesswire.com/news/home/20230418005388/en/
    New guidance from the American Academy of Otolaryngology-Head and Neck Surgery notes that radiofrequency treatments can be used to stabilize the nasal valve and optimize nasal valve collapse (NVC) patient outcomes.
  • VivAer, a non-invasive technology developed by Aerin Medical, uses temperature-controlled radiofrequency energy to provide long-term relief from nasal obstruction caused by NVC.
  • “Nasal airway obstruction is one of the primary reasons a patient visits an ENT physician, and we hope that this enables ENTs to treat nasal valve collapse with minimally invasive solutions when it contributes to nasal obstruction.”

SonarMed™ airway monitoring system Applauded by Frost & Sullivan for Providing Real-time Visualization for Accurate Troubleshooting with Its Endotracheal Tube Airway Monitor

Retrieved on: 
Thursday, December 8, 2022
Physician, Intubation, Huntington Hospital, ROI, LOS, Medtronic, UE, Environment, Airway obstruction, Ventilation, Patient, Radiation, Frost, NICU, FDA, Parent, Overalls, Caregiver, Marketing, Sleep, X-ray, ETT, Movement, Infant, SAN, UES, MBA, Acquisition, Medical device, Medical imaging

SAN ANTONIO, Dec. 8, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the neonatal care industry and, based on its analysis, recognizes the SonarMed™ airway monitoring system from Medtronic with the 2022 North America New Product Innovation Award. The SonarMed™ airway monitoring system is a unique technology intended to help reduce unplanned extubations (UE) during mechanical ventilation in the neonatal intensive care unit (NICU). The airway monitoring system allows for precise endotracheal tube (ETT) monitoring at the patient's bedside to prevent UE, a vital safety concern in the NICU. The system supports real-time ETT position and patency visualization.

Key Points: 
  • The SonarMedairway monitoring system is a unique technology intended to help reduce unplanned extubations (UE) during mechanical ventilation in the neonatal intensive care unit (NICU).
  • The airway monitoring system allows for precise endotracheal tube (ETT) monitoring at the patient's bedside to prevent UE, a vital safety concern in the NICU.
  • The SonarMed system enables accurate troubleshooting through timely alerts and precise measurements to handle a potentially critical event (tube movement or occlusion) and reduce UEs.
  • The system detects ETT tip movement and direction and alerts the physicians about potential ETT migration through custom and individualized alarms.

SonarMed™ airway monitoring system Applauded by Frost & Sullivan for Providing Real-time Visualization for Accurate Troubleshooting with Its Endotracheal Tube Airway Monitor

Retrieved on: 
Thursday, December 8, 2022
Physician, Intubation, Huntington Hospital, ROI, LOS, Medtronic, UE, Environment, Airway obstruction, Ventilation, Patient, Radiation, Frost, NICU, FDA, Parent, Overalls, Caregiver, Marketing, Sleep, X-ray, ETT, Movement, Infant, SAN, UES, MBA, Acquisition, Medical device, Medical imaging

SAN ANTONIO, Dec. 8, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the neonatal care industry and, based on its analysis, recognizes the SonarMed™ airway monitoring system from Medtronic with the 2022 North America New Product Innovation Award. The SonarMed™ airway monitoring system is a unique technology intended to help reduce unplanned extubations (UE) during mechanical ventilation in the neonatal intensive care unit (NICU). The airway monitoring system allows for precise endotracheal tube (ETT) monitoring at the patient's bedside to prevent UE, a vital safety concern in the NICU. The system supports real-time ETT position and patency visualization.

Key Points: 
  • The SonarMedairway monitoring system is a unique technology intended to help reduce unplanned extubations (UE) during mechanical ventilation in the neonatal intensive care unit (NICU).
  • The airway monitoring system allows for precise endotracheal tube (ETT) monitoring at the patient's bedside to prevent UE, a vital safety concern in the NICU.
  • The SonarMed system enables accurate troubleshooting through timely alerts and precise measurements to handle a potentially critical event (tube movement or occlusion) and reduce UEs.
  • The system detects ETT tip movement and direction and alerts the physicians about potential ETT migration through custom and individualized alarms.

Eagle Pharmaceuticals’ Investor Day to Feature World-Renowned KOLs on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

Retrieved on: 
Wednesday, November 16, 2022
Hypertension, Bradycardia, Ventilation, Itch, Hypoxia, Hypoventilation, Colonoscopy, Rash, GABA, Flumazenil, History, Placenta, Liver, III, Breast milk, Analgesic, ASA, Obstructive sleep apnea, Brain, Life, Safety, Patient, Apnea, Anaphylaxis, NMDA, Vital signs, Airway obstruction, Anesthesia, Maintenance, Benzodiazepine, Propofol, Hives, CNS, Patent, Government budget balance, CIV, Confusion, Systolic hypertension, Lethargy, Death, Hypotension, Hypotonia, IV, Human, Pregnancy, Bronchoscopy, Coma, Dentistry, Liquor, Pharmaceutical industry

WOODCLIFF LAKE, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the following speakers and world-renowned Key Opinion Leaders will be featured at the Company’s Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel, at 8:00am ET:

Key Points: 
  • Resuscitative drugs, and age- and size-appropriate equipment for bag-valve-maskassisted ventilation must be immediately available during administration of BYFAVO.
  • Concomitant use of benzodiazepines, including BYFAVO, and opioid analgesics may result in profound sedation, respiratory depression, coma, and death.
  • The sedative effect of intravenous BYFAVO can be accentuated by concomitantly administered CNS depressant medications, including other benzodiazepines and propofol.
  • BYFAVO is contraindicated in patients with a history of severe hypersensitivity reaction to dextran 40 or products containing dextran 40.

Apnimed to Present at the Stifel Healthcare Conference

Retrieved on: 
Tuesday, November 8, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Food, Diabetes, Hypertension, Sleep, Patient, FDA, Fast Track, CPAP, Population, Airway obstruction, Relaxation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cardiovascular disease, Apnea, Stroke, Sleep apnea, Fatigue, Central nervous system, Stifel, Obstructive sleep apnea, Quality of life, Risk, Pharmaceutical industry

Investors, please contact your representative at Stifel to schedule a live one-on-one meeting with Apnimed senior management being hosted November 15-16, 2022, during the conference.

Key Points: 
  • Investors, please contact your representative at Stifel to schedule a live one-on-one meeting with Apnimed senior management being hosted November 15-16, 2022, during the conference.
  • It is a potential first-in-class, novel, investigational combination dosed once daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity.
  • AD109 combines a selective norepinephrine reuptake inhibitor (atomoxetine) with Apnimeds novel selective antimuscarinic (aroxybutynin).
  • AD109 targets key neurological pathways in OSA that activate upper airway dilator muscles to maintain an open airway during sleep.

Apnimed to Participate in the 2nd Annual Needham Biotech Private Company Virtual 1x1 Forum

Retrieved on: 
Wednesday, October 12, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Quality of life, LinkedIn, Hypertension, Sleep apnea, Cardiovascular disease, Risk, Fatigue, Population, Stroke, CPAP, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Obstructive sleep apnea, Patient, Sleep, Relaxation, Twitter, Food, Airway obstruction, Diabetes, Fast Track, FDA, Central nervous system, Pharmaceutical industry

Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to treat obstructive sleep apnea (OSA) and related disorders, including its lead candidate AD109, today announced that company management will participate in the 2nd Annual Needham Biotech Private Company Virtual 1x1 Forum taking place October 18-19, 2022.

Key Points: 
  • Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to treat obstructive sleep apnea (OSA) and related disorders, including its lead candidate AD109, today announced that company management will participate in the 2nd Annual Needham Biotech Private Company Virtual 1x1 Forum taking place October 18-19, 2022.
  • It is a potential first-in-class, novel, investigational combination dosed once daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity.
  • AD109 targets key neurological pathways in OSA that activate upper airway dilator muscles to maintain an open airway during sleep.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Apnimed Expands Senior Leadership Team by Appointing John Cronin, M.D., Senior Vice President, Clinical Development

Retrieved on: 
Wednesday, October 5, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Quality of life, LinkedIn, Respironics, Pulmonology, CA, Hypertension, Sleep apnea, Georgetown University, Cardiovascular disease, Risk, Population, Stroke, Drug, CPAP, Obstructive sleep apnea, Patient, Mass General Brigham, Critical care, Relaxation, Research, Twitter, Multimedia, Senior, Coronavirus Scientific Advisory Board (Turkey), Medical director, Medical Affairs Bureau, Industry, Airway obstruction, Diabetes, FDA, Central nervous system, Duke University, Pharmaceutical industry, Sleep, Mass

Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that John Cronin, M.D., has joined the company as Senior Vice President, Clinical Development.

Key Points: 
  • Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that John Cronin, M.D., has joined the company as Senior Vice President, Clinical Development.
  • He will contribute immediately to the development and execution of clinical strategy for AD109, Apnimeds most advanced clinical candidate for obstructive sleep apnea (OSA), as well as help to enhance Apnimeds Medical Affairs team.
  • View the full release here: https://www.businesswire.com/news/home/20221005005126/en/
    Apnimed expands senior leadership team by appointing John Cronin, M.D., Senior Vice President, Clinical Development (Photo: Business Wire)
    John is a proven industry and clinical leader with deep experience and understanding of our therapeutic area, and we are excited to welcome him to the Apnimed team, said Larry Miller, M.D., Chief Executive Officer of Apnimed.
  • AD109 is currently completing Phase 2 clinical trials, after which Apnimed plans to meet with the FDA to discuss the Phase 3 development program.